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Meropenem/vaborbactam resistance in Klebsiella pneumoniae is associated with loss 
of function mutations in the OmpK35 and OmpK36 porins. Here we identify two 
previously unknown loss of function mutations that confer cefuroxime resistance in K. 
pneumoniae. The proteins lost were NlpD and KvrA; the latter is a transcriptional 
repressor controlling capsule production. We demonstrate that KvrA loss reduces 
OmpK35 and OmpK36 porin production, which confers reduced susceptibility to 





Carbapenems are often reserved as a last resort for treatment of severe infections caused by 
multi-drug resistant Gram-negative bacteria. A rise in the prevalence of cephalosporin 
resistance, particularly due to the spread of mobile cephalosporinase genes in the 
Enterobacteriaceae has resulted in the increased use of carbapenems worldwide. This has 
driven the emergence of carbapenem resistant Enterobacteriaceae (CRE) which are classed 
as one of the greatest threats to human health according to the World Health Organisation. In 
Klebsiella pneumoniae, carbapenem resistance is mainly mediated by the production of a 
carbapenemase. In some parts of the world the most prevalent is the class A carbapenemase 
KPC; in others, most common are the class B metallo-β-lactamases e.g. NDM; in others, class 
D carbapenemases e.g. OXA-48 like enzymes predominate (1-3). CRE can also emerge due 
to mutations that reduce envelope permeability, for example those that result in porin 
deficiency, and particularly when these mutations occur in isolates producing CTX-M or 
AmpC-type cephalosporinases (4). Indeed, most carbapenem resistant K. pneumoniae clinical 
isolates have multiple resistance mechanisms, including permeability defects (5-8). 
As part of our work aiming to identify novel mechanisms for reduced cephalosporin and/or 
carbapenem permeability in K. pneumoniae, the oqxR and ramR double mutant, FQ3, derived 
from K. pneumoniae Ecl8 as previously described (9) was used as a parent strain to select 
cephalosporin resistant mutants. FQ3 overproduces two efflux pumps; AcrAB and OqxAB, 
resulting in resistance to fluoroquinolones, chloramphenicol and minocycline (9). One hundred 
microlitre aliquots of overnight cultures grown in Nutrient Broth (NB) were spread onto Mueller 
Hinton Agar containing 16 µg.mL-1 cefuroxime, which were then incubated for 24 h. One 
representative mutant derivative was named “FQ3 M1” and was shown by disc susceptibility 
testing, performed and interpreted according to CLSI methodology (10, 11) to be resistant to 
cefuroxime, cefoxitin and cephalexin (Table 1). MICs were determined for a selected group of 
antimicrobials, confirming cefuroxime and cefoxitin resistance, and revealing small increases 
in the MICs of third generation cephalosporins and aztreonam against FQ3 M1, but these 
remained in susceptible ranges (Table 1). 
Changes in envelope protein abundance in mutant FQ3 M1 relative to FQ3 were quantified 
using LC-MS/MS proteomics as previously described (12) to identify potential reasons for 
cephalosporin resistance. There were 15 proteins significantly altered (Table 2). Amongst this 
group of proteins with uncertain or metabolic functions, were the important antimicrobial entry 
porins OmpK35 and OmpK36, which were both downregulated in FQ3 M1 by almost 3-fold.  
We next used WGS, aiming to explain the downregulation of OmpK35 and OmpK36 in mutant 




HiSeq 2500 instrument (Illumina, San Diego, CA, USA). Reads were trimmed using 
Trimmomatic (13) and assembled into contigs using SPAdes 3.10.1 
(http://cab.spbu.ru/software/spades/). Assembled contigs were mapped to the K. pneumoniae 
Ecl8 reference genome (GenBank accession number GCF_000315385.1) by using 
progressive Mauve alignment software (14).  
No mutations were detected in ompK36 and ompK35 or adjacent sequences, or in known 
regulators of porin production, e.g. OmpR/EnvZ (15). In fact, FQ3 M1 has three separate 
mutations relative to FQ3: a frameshift mutation (causing Asn278FS) in nlpD, a frameshift 
(causing Asp395FS) in dhaR, and a 1,159 bp deletion spanning kvrA and the adjacent genes, 
ydhI and ydhJ. In Escherichia coli, NlpD is involved in peptidoglycan remodelling during cell 
division (16-18). DhaR is a transcriptional activator responsible for controlling the production 
of the metabolic enzymes glycerol dehydrogenase and dihydroxyacetone kinase (19,20). KvrA 
is a MarR-type transcriptional repressor with a key role in K. pneumoniae capsulation (21-23).  
In order to deconvolute the possible roles of the three different loss of function mutations, we 
separately insertionally inactivated nlpD, dhaR, kvrA, and also ompK36 as controls in FQ3.  
Mutants were constructed using the pKNOCK suicide plasmid (24). DNA fragments of the 
genes to be inactivated were amplified with Phusion High-Fidelity DNA Polymerase (NEB, UK) 
from K. pneumoniae Ecl8 genomic DNA by using primers ompK36 KO FW (5′-
CGTTCAGGCGAACAACACTG-3′) and ompK36 KO RV (5′-AAGTTCAGGCCGTCAACCAG-
3′); kvrA KO FW (5’-ATCTGGCACGTTTAGTTCGC-3’) and kvrA KO RV (5’-
CCCTTTCTCCTCCAGCTGAT-3’); dhaR KO FW (5’-CAATCAGATGTACGGCCTGC-3’) and 
dhaR KO RV (5’-GACTTCGACGTGATTCAGGC-3’); nlpD KO FW (5’-
ACGATTTCCGCGACCTGGCG-3’) and nlpD KO RV (5’- CAACATCTTGGTAGCACTCT-3’). 
Each PCR product was separately ligated into the pKNOCK-GM at the SmaI site and each 
recombinant plasmid was then transferred into FQ3 cells by conjugation from E. coli 
BW20767. Mutants were selected using gentamicin (5 µg.mL-1) and the mutations were 
confirmed by PCR using primers ompK36 full length FW (5’-GAGGCATCCGGTTGAAATAG-
3’) and ompK36 full length RV (5’-ATTAATCGAGGCTCCTCTTAC-3’); kvrA full length FW (5’-
ACTTAGCAAGCTAATTATAAGGAGATGA-3’) and kvrA full length RV (5’-
GCCGCAAAGAATTAATCTTTA-3’); dhaR full length FW (5’- CAGCCCGATGGACGAGATT-
3’) and dhaR full length RV (5’- TATTGGGCTCAGCGCGTCC-3’); nlpD full length FW (5’-
GTCGGCGAAGAGCATCAGT-3’) and nlpD full length RV (5’-CACCTTCCACGGCACATCA-
3’). 
Inactivating dhaR in FQ3 had no effect on cephalosporin MIC, determined using CLSI 




in both cases the MIC was one doubling dilution lower than against FQ3 M1 (Table 3). A 
similar effect was observed upon disruption of ompK36, adding further weight to the 
hypothesis that porin downregulation is involved in the phenotype acquired by FQ3 M1. Whilst 
ompK35 disruption did not affect cephalosporin MICs, FQ3 already has downregulated 
OmpK35 production due to mutations in ramR and oqxR (9). We next complemented kvrA in 
FQ3 M1. To do this, kvrA DNA was amplified from K. pneumoniae Ecl8 genomic DNA by using 
primers (introduced restriction sites underlined): kvrA full length BamHI FW (5’-
AAAGGATCCCGGCAATCCGGATGTGTTAAGAC-3’) and kvrA full length SalI RV (5’-
AAAGTCGACGGAGGGTGAAAAAAGGCCCGGATTA-3’). The PCR product was digested 
and inserted to pUBYT (26) cut with BamHI and SalI to generate pUBYT::kvrA. The 
recombinant plasmid was then transferred into FQ3 M1 cells by electroporation. The 
transformants were selected using kanamycin (50 µg.mL-1) and the presence of plasmids was 
confirmed by PCR using primers pUBYT check FW (5’-GCAAGAAGGTGATGAATCTACA-3’) 
and pUBYT check RV (5’-GTGGCAGCAGCCAACTCA-3’). Complementation of FQ3 M1 with 
pUBYT::kvrA showed that the MICs of cefoxitin and cefuroxime reduced, but again not to a 
value as low as against FQ3. This confirmed the result of the gene inactivation experiment 
that kvrA loss alone is not the sole determinant of the cephalosporin resistant phenotype 
expressed by FQ3 M1 (Table 3).  
Given that inactivation of either kvrA or nlpD in FQ3 reduced cephalosporin susceptibility, we 
performed LC-MS/MS envelope proteomics for these mutants versus FQ3 as above, which 
revealed that mutation in kvrA caused a reduction in OmpK35 and OmpK36 porin levels in 
FQ3, to the same extent as seen in FQ3 M1. Mutation in nlpD, despite altering cephalosporin 
MIC, did not (Fig. 1 A, B). Of the proteomic changes, in addition to OmpK35 and OmpK36, 
seen in FQ3 M1 versus FQ3, only 4/13 proteins were similarly up/down regulated upon 
disruption of kvrA in FQ3 (Table 2). Because FQ3 is derived from Ecl8, a laboratory strain, 
and because FQ3 carries mutations that increase efflux pump and reduce OmpK35 porin 
production (9), we wanted to test the impact of kvrA inactivation in a wild-type clinical isolate. 
To do this, we insertionally inactivated kvrA (as above) in the susceptible K. pneumoniae 
clinical isolate KP47, which has wild-type envelope permeability (27) and showed by LC-
MS/MS that OmpK35 and OmpK36 levels fell in this mutant relative to KP47, approximately 
3-fold, as seen in FQ3. Porin abundance did not change upon nlpD inactivation in KP47, as 
also seen in FQ3 (Fig. 1 C, D). 
β-Lactamase inhibitors such as clavulanic acid, tazobactam and sulbactam have been 
successful in overcoming resistance to penicillin derivatives, e.g. amoxicillin, piperacillin and 
ticarcillin in Enterobacteriaceae. However, inhibitor/penicillin combinations are not clinically 




those producing metallo-β-lactamases (28). This has led to the development of new β-
lactam/β-lactamase inhibitor combinations, and one recently licenced for clinical use is 
meropenem/vaborbactam (29-32).).  
Meropenem/vaborbactam resistance in KPC-producing K. pneumoniae has been shown to 
occur by loss of function mutation in ompK35 and ompK36 (33,34). We therefore wanted to 
test the impact of OmpK35/36 porin reduction seen following inactivation of kvrA in K. 
pneumoniae KP47 (Fig. 1C) on meropenem/vaborbactam susceptibility when the mutant 
produces KPC. To investigate this, we used pUBYT::blaKPC-3 (26) to transform K. pneumoniae 
KP47, KP47ΔkvrA and KP47ΔompK36 (as a control). As expected, due to carriage of KPC, 
all transformants were resistant to meropenem. Addition of vaborbactam (8 µg.mL-1) reduced 
the meropenem MIC against KP47 well into the susceptible range. In contrast, 
meropenem/vaborbactam MICs against the kvrA and ompK36 mutants were 1 µg.mL-1 (four 
doubling dilutions higher than against KP47) and 32 µg.mL-1 respectively, due to the 
production of KPC. The meropenem/vaborbactam MIC against FQ3 ΔkvrA::blaKPC-3 was also 
raised by 3 doubling dilutions to become 1 µg.mL-1. Disruption of nlpD in FQ3 or KP47 did not 
significantly raise meropenem/vaborbactam MIC (Table 4) as expected because it has no 
effect on porin abundance (Fig. 1). Hence, even in an otherwise wild-type (27) KPC-producing 
clinical K. pneumoniae isolate, OmpK35/36 downregulation caused solely by kvrA mutation is 
enough to reduce meropenem/varborbactam susceptibility. There was no change in 
susceptibility to ciprofloxacin, minocycline or chloramphenicol in KP47 ΔkvrA or KP47 ΔnlpD 
relative to KP47, confirming that the effects of these mutations are β-lactam focussed. We 
cannot say for other classes because resistance is caused by acquired mechanisms. 
NlpD (“new lipoprotein D”) is conserved across Gram-negative bacteria, with essential roles 
in virulence, e.g. in Yersinia pestis (35). In E. coli it is recruited to the division site where it 
targets the activity of the peptidoglycan amidase AmiC, to which it binds. Loss of NlpD in E. 
coli is known to delay the onset of cell lysis after treatment with ampicillin because 
peptidoglycan breakdown by AmiC is less targeted to the division site (36,37). This provides 
a clear rationale for why disruption of nlpD reduces β-lactam susceptibility in K. pneumoniae 
(Table 1), but its role as a mediator of cefuroxime resistance has not previously been 
suspected. 
We also report that inactivation of kvrA causes cefuroxime resistance in K. pneumoniae, but 
more importantly, it causes reduced susceptibility to meropenem/vaborbactam, even in an 
otherwise wild-type K. pneumoniae clinical isolate transformed to express blaKPC-3 from its 
native promoter in a low copy number vector (26). We show that cefuroxime resistance and 




and OmpK36 downregulation. This is reminiscent of OmpR mutations in E. coli, which reduce 
OmpF and OmpC production and can also affect antimicrobial susceptibility (38).  
KvrA is a MarR-family transcriptional repressor. Importantly, we found that YdhJ is upregulated 
45-fold (p=0.002, n=3) and >100-fold (p<0.0001, n=3) according to proteomics following 
disruption of kvrA in K. pneumoniae KP47 and FQ3, respectively. YdhJ is encoded within a 
putative efflux pump operon adjacent to kvrA on the chromosome. Expression of the 
homologue of this ydhIJK operon in E. coli is directly repressed by SlyA (39), which is encoded 
upstream of ydhIJK, in an almost identical arrangement as kvrA and ydhIJK in K. pneumoniae. 
Therefore, the ydhIJK operon is likely to be the direct repressive target of KvrA in this species, 
with its wider activatory effects being indirect. Similar characterised MarR-family repressors 
such as SlyA also tend to have local direct repressive effects, but cause activation of gene 
expression at some promoters indirectly by blocking the repressive activity of H-NS at those 
promoters (40). Since H-NS is known to have a repressive effect on porin production in E. coli 
(41) it may well be that increased repressive activity of H-NS in the absence of KvrA is the 
explanation for OmpK35/36 downregulation seen in K. pneumoniae following loss of function 
mutation in kvrA. 
Disruption of kvrA also causes downregulation of key capsule biosynthesis genes, e.g. galF, 
manC and wzi in some K. pneumoniae strains (21). We found using proteomics that Wzi was 
downregulated a marginal 0.82-fold (p=0.03, n=3) upon disruption of kvrA in isolate KP47 but 
not GalF or ManC and none of these proteins were downregulated in FQ3 ΔkvrA versus FQ3. 
However, it is known that kvrA loss does not reduce capsule production is all strains, and nor 
does it attenuate the virulence of all strains in a mouse infection model (21). Among 455 
isolates of K. pneumoniae from NCBI database, we found 9 isolates (Genbank accession 
numbers CP037927, LR134162, CP032175, CP018056, CP003200, LR588409, CP044039, 
CP043670, CP043669) where kvrA was mutated in a way predicted to result in a truncated 
and presumably non-functional KvrA. One key example is the KPC-2 and CTX-M-14 producing 
carbapenem resistant human sputum isolate HS11286 (42, 43). This confirms that kvrA 
mutants are present in human clinical samples. 
In conclusion, we report here two loss of function mutations in genes previously not known to 
affect antimicrobial susceptibility in K. pneumoniae. Both cause early generation 
cephalosporin resistance, using two different mechanisms. The mechanism stimulated by 
kvrA loss is reduced porin production, and, importantly, this reduces susceptibility to one of 
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Figure 1. Normalised abundance of OmpK35 and OmpK36 porins in K. pneumoniae 
kvrA and nlpD mutants. 
OmpK36 and OmpK35 abundances were measured using LC-MS/MS and normalised to the 
abundance of OmpA, to control for protein loading. Data presents mean ± standard error of 
the mean, n=3. Asterisk (*) indicates statistically significant differences from the parental 
strains by t-test (p<0.05). (A) OmpK36 to OmpA protein ratio and (B) OmpK35 to OmpA 
protein ratio in FQ3 and its mutant derivatives. (C) OmpK36 to OmpA protein ratio and (D) 






Table 1. Susceptibility testing for antimicrobials against K. pneumoniae FQ3 and 
cefuroxime resistant mutant FQ3 M1. 
Antimicrobial 





Disc Test  
 
MIC 
Meropenem S 0.125 S 0.125 
Ertapenem S  S  
Imipenem S  S  
Doripenem S  S  
Aztreonam S 0.0625 S 0.125 
Cefepime S  S  
Ceftazidime S 0.125 S 0.25 
Cefotaxime S 0.25 S 1 
Ceftriaxone S  S  
Ceftizoxime S  S  
Cefoperazone S  S  
Cefotetan S  S  
Cefoxitin S 8 R 64 
Cefuroxime S 8 R 64 
Cephalexin S  R  
Ciprofloxacin R 8 R 8 
Norfloxacin R  R  
Ofloxacin R  R  
Levofloxacin R  R  
Chloramphenicol R 128 R 128 
Minocycline R 16 R 16 
Amikacin S 1 S 2 
Gentamicin S  S  
 













FQ3 M1 (1) 
Abundance 
FQ3 M1 (2) 
Abundance 




A6T518 Phosphoheptose isomerase, GmhA  - - - 1.18E+08 2.05E+07 2.02E+07 <0.0005 >20 
A6T720 Aspartate aminotransferase, AspC  - - - 2.11E+07 1.92E+07 2.27E+07 <0.0005 >20 
A6TBN4 ATP-binding component of methyl-
galactoside transporter, MglA  
- - - 2.64E+07 2.11E+07 3.40E+07 <0.0005 >20 
A6TF45 sn-glycerol-3-phosphate dehydrogenase, 
GlpD  
3.10E+07 1.21E+07 3.24E+07 2.37E+08 1.24E+09 1.72E+09 
0.004 42.43 
A6T5Q5 Putative outer membrane protein  4.62E+08 3.06E+08 4.48E+08 1.61E+09 1.85E+09 1.51E+09 <0.0005 4.09 
A6TBM3 Putative channel/filament proteins, YohG  2.93E+08 2.57E+08 4.77E+08 9.04E+08 1.04E+09 1.31E+09 <0.0005 3.16 
A6T4Y7 Acetyl-coenzyme A carboxylase carboxyl 
transferase, AccA  
1.24E+08 8.31E+08 4.06E+08 1.15E+09 7.38E+08 9.36E+08 0.005 2.07 
A6T8N5 Putative uncharacterized protein, YdgH  6.65E+08 5.22E+08 8.53E+08 3.69E+08 3.61E+08 3.44E+08 0.001 0.53 
A6T721 OmpK35 porin  1.19E+10 7.32E+09 7.82E+09 2.89E+09 3.97E+09 3.01E+09 0.001 0.36 
A6TBT2 OmpK36 porin  3.49E+10 3.13E+10 3.41E+10 1.12E+10 1.31E+10 1.00E+10 <0.0005 0.34 
A6TD34 Lipoprotein, NlpD  9.15E+08 7.51E+08 1.14E+09 2.64E+08 1.68E+08 3.13E+08 <0.0005 0.27 
A6T4Y4 Lipid-A-disaccharide synthase, LpxB   6.06E+07 5.19E+07 1.02E+08 - - - <0.0005 <0.005 
A6T9Z3 Putative multidrug resistance protein, YdhJ  7.23E+07 6.50E+07 9.18E+07 - - - <0.0005 <0.005 
A6TBM5 Putative cellobiose-specific PTS permease 2.83E+07 1.66E+07 3.57E+07 - - - <0.0005 <0.005 
A6TEA5 Putative glycerol dehydrogenase, DhaD  5.00E+07 2.28E+08 2.51E+08 - - - <0.0005 <0.005 
Strains were grown in Cation-Adjusted Muller-Hinton broth and raw abundance data are provided for three biological replicates of parent (FQ3) 2 
and mutant (FQ3 M1). Analysis was as described in (9) and proteins listed are those with significantly different abundance in FQ3 M1 versus 3 




Table 3. MICs (µg.mL-1) of cephalosporins against K. pneumoniae Ecl8 FQ3 and mutant 5 
derivatives. 6 
 Cefuroxime MIC Cefoxitin MIC 
FQ3 8 8 
FQ3 ΔdhaR 8 8 
FQ3 ΔompK35 8 8 
FQ3 ΔkvrA 16 32 
FQ3 ΔnlpD 32 32 
FQ3 ΔompK36 32 32 
FQ3 M1 64 64 
FQ3 M1(pUBYT) 32 64 
FQ3 M1(pUBYT::kvrA) 16 16 
 7 
The CLSI susceptible and resistance breakpoints (11) for cefuroxime and cefoxitin are ≤8 and 8 




Table 4. MICs (µg.mL-1) of meropenem against K. pneumoniae clinical isolate KP47 and 10 
mutant derivatives measured with and without 8 µg.mL-1 of vaborbactam. 11 
 12 
 Meropenem MIC Meropenem/Vaborbactam MIC 
KP47/pKPC-3 128 0.0625/8 
KP47 ΔompK36/pKPC-3 >256 32/8 
KP47 ΔnlpD/pKPC-3 128 0.25/8 
KP47 ΔkvrA/pKPC-3 256 1/8 
FQ3/pKPC-3 128 0.125 
FQ3 ΔnlpD /pKPC-3 256 0.125 
FQ3 ΔkvrA/pKPC-3 >256 1 
 13 
The CLSI susceptible and resistance breakpoints (11) for meropenem are ≤1 and ≥4 µg.mL-1 14 
in the absence and ≤4 and ≥16 µg.mL-1 in the presence of 8 µg.mL-1 vaborbactam. Values are 15 
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